---
url: https://www.servicesaustralia.gov.au/neuromyelitis-optica-spectrum-disorder-nmosd
title: Neuromyelitis optica spectrum disorder (NMOSD) - Health professionals - Services AustraliaServices AustraliaServices Australia
scrapedAt: 2026-02-20T21:41:22.806Z
source: servicesaustralia.gov.au
---
# Neuromyelitis optica spectrum disorder

The PBS subsidises ravulizumab for patients with neuromyelitis optica spectrum disorder (NMOSD).

## on this page

-   [Patient eligibility](#a1)
-   [Section 100 arrangements](#a2)
-   [Authority applications](#a3)
-   [Applying for initial grandfather treatment](#a4)
-   [Applying for continuing treatment](#a5)
-   [More information](#a6)

## Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with ravulizumab under the _National Health Act 1953_, section 100 for patients with NMOSD.

Patients must be eligible for the [PBS](/pharmaceutical-benefits-scheme) and meet the relevant restriction criteria.

The [Schedule of Pharmaceutical Benefits](http://www.pbs.gov.au/pbs/home) on the PBS website outlines the restrictions for prescribing ravulizumab.

## Section 100 arrangements

### ravulizumab

This item is only PBS-subsidised for non-admitted patients, day admitted patients, or patients on discharge who are attending either:

-   an approved private hospital
-   a public hospital.

This item isn’t PBS-subsidised for public hospital in-patients. You must include the hospital name and provider number on the authority application form.

### Treatment specifics

To be eligible for PBS-subsidised treatment with ravulizumab, patients must be treated by either a:

-   neurologist
-   medical practitioner in consultation with a neurologist.

## Authority applications

### Applying for initial treatment

Please note: You don’t need to complete this application in writing when you request [PBS authority online](/apply-for-pbs-authority?context=20#accordion1).

Applications for initial authority approval to prescribe PBS-subsidised ravulizumab to treat NMOSD can be made:

-   using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20#accordion1)
-   in writing and use [HPOS Form upload](/hpos?context=20)
-   in writing and mail to [PBS Complex Drugs Programs](/health-professionals-contact-information?context=20#complexdrugs).

All written applications must include:

-   details of the proposed prescription or prescriptions
-   the completed [Neuromyelitis optica spectrum disorder - ravulizumab - initial authority application form](/pb382?context=20)
-   relevant attachments.

## Applying for initial grandfather treatment

Please note: You don’t need to complete this application in writing when you request [PBS authority online](/apply-for-pbs-authority?context=20#accordion1).

Applications for initial grandfather authority approval to prescribe PBS-subsidised ravulizumab to treat NMOSD can be made:

-   using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20#accordion1)
-   in writing and use [HPOS Form upload](/hpos?context=20)
-   in writing and mail to [PBS Complex Drugs Programs](/health-professionals-contact-information?context=20#complexdrugs).

All written applications must include:

-   details of the proposed prescription or prescriptions
-   the completed [Neuromyelitis optica spectrum disorder - ravulizumab - initial grandfather authority application form](/pb383?context=20)
-   relevant attachments.

## Applying for continuing treatment

Applications for continuing authority approval to prescribe PBS-subsidised ravulizumab to treat NMOSD can be made either:

-   in real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   by calling the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs).

## More information

Call the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs) for more information.
